SCHEMBL23728207

SCHEMBL23728207

[CH]=C1OC(=O)c2c(O)cccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.52
MAPT P10636 8/20 0.50
ALDH1A1 P00352 5/20 0.50
TDP1 Q9NUW8 5/20 0.50
MAPK1 P28482 4/20 0.50
ALOX15 P16050 4/20 0.50
HSD17B10 Q99714 4/20 0.50
HPGD P15428 3/20 0.50
TSHR P16473 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
LMNA P02545 1/20 0.50
MAOB P27338 1/20 0.50
HTT P42858 1/20 0.50
KMT2A Q03164 7/20 0.47
MEN1 O00255 6/20 0.47
KDM4E B2RXH2 5/20 0.47
RECQL P46063 5/20 0.47
USP2 O75604 4/20 0.47
CYP3A4 P08684 4/20 0.47
AURKA O14965 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28329949 0.81 MAOA (0.58) MAOAMAPTALDH1A1TDP1MAPK1
SCHEMBL29568960 0.81 MAOA (0.58) MAOAMAPTALDH1A1TDP1MAPK1
SCHEMBL382951 0.81 MAOA (0.58) MAOAMAPTALDH1A1TDP1MAPK1
SCHEMBL27446937 0.76 MAOA (0.52) MAOAMAPTALDH1A1TDP1MAPK1
SCHEMBL9137817 0.74 MAOA (0.55) MAOAMAPTALDH1A1TDP1MAPK1
Phenol SCHEMBL28098189 0.73 MAOA (0.48) MAOAMAPTALDH1A1TDP1MAPK1
SCHEMBL9145106 0.72 MAOA (0.47) MAOAMAPTALDH1A1TDP1MAPK1
Dimethyl Sulfoxide SCHEMBL28038423 0.72 MAOA (0.47) MAOAMAPTALDH1A1TDP1MAPK1
SCHEMBL9145121 0.72 MAOA (0.47) MAOAMAPTALDH1A1TDP1MAPK1
SCHEMBL28038030 0.72 MAOA (0.47) MAOAMAPTALDH1A1TDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US disclosed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB MAOA 3718/4885MAPT 3926/4885ALDH1A1 2722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.